The Promise of Fibroblasts

• Fibroblast cells are responsible for the production of collagen and other extra cellular matrix proteins.
• The fibroblast cells in LAVIV™ are native to the recipient and recognized by the body’s immune system as “self”.
• Potential applications extend beyond Dermatology.

Scientific Rigor

Our proprietary, autologous cellular technology platform has broad market potential. Through this platform, we plan to develop evidence-based, cutting-edge products that take personalized medicine to the next level. Our commitment to scientific rigor is demonstrated by:

• Extensive clinical trials for LAVIV™, the first and only aesthetic cellular therapy approved by the FDA
• Robust intellectual property, with 10 US patents and 30 patents in other countries
• State-of-the-art, FDA-approved manufacturing facilities
• Research and development partnership with UCLA